Multi-target Chimaeric VLP As a Therapeutic Vaccine in a Model of Colorectal Cancer

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2017 Aug 16

PMID 28806910

Citations 19

Authors

Braeden Donaldson

Farah Al-Barwani

Simon J Pelham

Katie Young

Vernon K Ward

Sarah L Young

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targeted immune responses against tumour-associated antigens. In this study, we have developed chimaeric virus-like particles (VLP), a form of non-infectious non-replicative subunit vaccine consisting of rabbit haemorrhagic disease virus (RHDV) VP60 capsid proteins containing recombinantly inserted epitopes from murine topoisomerase IIα and survivin. These vaccines were developed in mono- (T.VP60, S.VP60) and multi-target (TS.VP60) forms, aiming to elucidate the potential benefits from multi-target vaccination.

Methods: Chimaeric RHDV VLP were developed by recombinantly inserting immune epitopes at the N-terminus of VP60. Vaccines were tested against a murine model of colorectal cancer by establishing MC38-OVA tumours subcutaneously. Unmethylated CpG DNA oligonucleotides (CpGs) were used as a vaccine adjuvant. Statistical tests employed included the Mantel-Cox log-rank test, ANOVA and unpaired t-tests depending on the data analysed, with a post hoc Bonferroni adjustment for multiple measures.

Results: Chimaeric RHDV VLP were found to form a composite particle in the presence of CpGs. Overall survival was significantly improved amongst mice bearing MC38-OVA tumours following vaccination with T.VP60 (60%, 9/15), S.VP60 (60%, 9/15) or TS.VP60 (73%, 11/15). TS.VP60 significantly prolonged the vaccine-induced remission period in comparison to each mono-therapy.

Conclusions: Chimaeric VLP containing multiple epitopes were found to confer an advantage for therapeutic vaccination in a model of colorectal cancer based on the prolongation of remission prior to tumour escape.

Citing Articles

Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.

Ning W, Yan S, Song Y, Xu H, Zhang J, Wang X Front Immunol. 2025; 15():1504124.

PMID: 39840069 PMC: 11747419. DOI: 10.3389/fimmu.2024.1504124.

Personalized nanovaccines for treating solid cancer metastases.

Feng T, Hu J, Wen J, Qian Z, Che G, Zhou Q J Hematol Oncol. 2024; 17(1):115.

PMID: 39609851 PMC: 11603676. DOI: 10.1186/s13045-024-01628-4.

Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances.

Tousian B, Khosravi A, Ghasemi M, Kadkhodaie M Mater Today Bio. 2024; 27:101134.

PMID: 39027676 PMC: 11255118. DOI: 10.1016/j.mtbio.2024.101134.

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.

Shebbo S, Binothman N, Darwaish M, Niaz H, Abdulal R, Borjac J Front Immunol. 2024; 15:1350208.

PMID: 38533510 PMC: 10963412. DOI: 10.3389/fimmu.2024.1350208.

Potential Application of Self-Assembled Peptides and Proteins in Breast Cancer and Cervical Cancer.

Zhang S, Chen M, Geng Z, Liu T, Li S, Yu Q Int J Mol Sci. 2023; 24(23).

PMID: 38069380 PMC: 10706889. DOI: 10.3390/ijms242317056.

References

Lee S, Sin J . MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model. Hum Vaccin Immunother. 2015; 11(8):2012-20. PMC: 4635946. DOI: 10.1080/21645515.2015.1016669. View

Adachi N, Nomoto M, Kohno K, Koyama H . Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene. 2000; 245(1):49-57. DOI: 10.1016/s0378-1119(00)00040-8. View

Hammarstrom S . The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999; 9(2):67-81. DOI: 10.1006/scbi.1998.0119. View

Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H . Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016; 166-167:48-58. DOI: 10.1016/j.clim.2016.03.015. View

Phuphanich S, Wheeler C, Rudnick J, Mazer M, Wang H, Nuno M . Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2012; 62(1):125-35. PMC: 3541928. DOI: 10.1007/s00262-012-1319-0. View

Park J, Chang H, Kim B, Yeo H, Kim D . Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer. Colorectal Dis. 2013; 15(9):e503-11. DOI: 10.1111/codi.12304. View

Li K, Peers-Adams A, Win S, Scullion S, Wilson M, Young V . Antigen incorporated in virus-like particles is delivered to specific dendritic cell subsets that induce an effective antitumor immune response in vivo. J Immunother. 2012; 36(1):11-9. DOI: 10.1097/CJI.0b013e3182787f5e. View

Hermans I, Silk J, Yang J, Palmowski M, Gileadi U, McCarthy C . The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods. 2004; 285(1):25-40. DOI: 10.1016/j.jim.2003.10.017. View

Duggan M, Jochems C, Donahue R, Richards J, Karpa V, Foust E . A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas. Cancer Immunol Immunother. 2016; 65(11):1353-1364. PMC: 5071149. DOI: 10.1007/s00262-016-1893-7. View

10.

Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T . Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2014; 21(2):312-21. DOI: 10.1158/1078-0432.CCR-14-0202. View

11.

Park J, Kim H, Park M, Kim C, Chung Y, Hong Y . Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope. Cancer Immunol Immunother. 2009; 59(5):747-57. PMC: 11030946. DOI: 10.1007/s00262-009-0795-3. View

12.

Rodriguez F, Harkins S, Slifka M, Whitton J . Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol. 2002; 76(9):4251-9. PMC: 155093. DOI: 10.1128/jvi.76.9.4251-4259.2002. View

13.

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

14.

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

15.

Andersen M, Marie Svane I, Becker J, Straten P . The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007; 13(20):5991-4. DOI: 10.1158/1078-0432.CCR-07-0686. View

16.

Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S . Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014; 63(4):381-94. PMC: 11029529. DOI: 10.1007/s00262-013-1516-5. View

17.

Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P . Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol. 2013; 52(5):919-32. DOI: 10.3109/0284186X.2013.764008. View

18.

Jemon K, Young V, Wilson M, McKee S, Ward V, Baird M . An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy. PLoS One. 2013; 8(6):e66866. PMC: 3682997. DOI: 10.1371/journal.pone.0066866. View

19.

Storni T, Ruedl C, Schwarz K, Schwendener R, Renner W, Bachmann M . Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol. 2004; 172(3):1777-85. DOI: 10.4049/jimmunol.172.3.1777. View

20.

Wang X, Xu F, Liu J, Gao B, Liu Y, Zhai Y . Atomic model of rabbit hemorrhagic disease virus by cryo-electron microscopy and crystallography. PLoS Pathog. 2013; 9(1):e1003132. PMC: 3547835. DOI: 10.1371/journal.ppat.1003132. View